Many doctors and consumer advocates fear that the tech industry, which lives by the mantra "fail fast and fix it later," is putting patients at risk.

Hundreds of employers now include stem cell therapy in their insurance coverage, but is it worth the cost?

The high cost of cutting-edge tests and treatments is threatening to keep precision medicine out of reach for many patients.

An exclusive analysis for Kaiser Health News found that only 48 percent of eligible breast cancer patients today get a recommended shorter radiation regimen, in spite of the additional costs and inconvenience of the longer type.